Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 9 citing articles:

Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Elena Catanzaro, Manuel Beltrán‐Visiedo, Lorenzo Galluzzi, et al.
Cellular and Molecular Immunology (2024)
Open Access | Times Cited: 8
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
Nicolas Roussot, Courèche Kaderbhaï, François Ghiringhelli
Cancers (2025) Vol. 17, Iss. 5, pp. 906-906
Open Access | Times Cited: 1
Targeted and cytotoxic inhibitors used in the treatment of lung cancers
Robert Roskoski
Pharmacological Research (2024), pp. 107465-107465
Open Access | Times Cited: 4
Regimen Selection for Chemoimmunotherapy in Non-Squamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multi-Center Retrospective Cohort Study
Tae Hata, Tadaaki Yamada, Yasuhiro Gotô, et al.
Clinical Lung Cancer (2025)
Closed Access
Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
Meifeng Luo, Huiting Wei, Moqin Qiu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Update 2025: Management of Non‑Small-Cell Lung Cancer
Hyein Jeon, Shuai Wang, Junmin Song, et al.
Lung (2025) Vol. 203, Iss. 1
Open Access
Real-World Evaluation of Immune-Related Endocrinopathies in Metastatic NSCLC Patients Treated with ICIs in Romania
Simona Coniac, Mariana Costache-Outas, Ionuț-Lucian Antone-Iordache, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1198-1198
Open Access
Letter Re: Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
Mansi Agrawal, Adwaith Krishna Surendran, Rakesh Biswas
European Journal of Cancer (2025), pp. 115442-115442
Closed Access
Impact of Platinum-Based Chemotherapy and CTLA-4 Inhibition on Acquired Resistance to First-Line Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer: A Systematic Review and Reconstructed Individual Patient Data Analysis
Sara Oresti, Fabio Salomone, A. Nuccio, et al.
(2025)
Closed Access
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis
Solange Peters, Luis Paz‐Ares, Martin Reck, et al.
Journal of Thoracic Oncology (2024) Vol. 20, Iss. 1, pp. 94-108
Open Access | Times Cited: 3
Evolving Patient-Centred Therapies for Metastatic NSCLC
OPEN Health Scientific Communications
EMJ Oncology (2024), pp. 39-48
Open Access
Page 1

Scroll to top